Bristol-Myers Squibb Stock: Balanced Segment Growth, Pullback Is An Opportunity (NYSE:BMY)
· seekingalpha.com
Bristol-Myers Squibb is reiterated as a buy, offering attractive valuation and a high 4.23% dividend yield. Click to read more about the BMY stock.
Health care-sector stocks soared from May through mid-August, right in the heart of the “broadening trade” that benefited areas away from tech. Yes, it has ...